tetano
Editor, Senior Moderator
Transfus Clin Biol
. 2021 May 7;S1246-7820(21)00073-2.
doi: 10.1016/j.tracli.2021.05.003. Online ahead of print.
Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants
Manish Raturi[SUP] 1 [/SUP], Anuradha Kusum[SUP] 2 [/SUP], Mansi Kala[SUP] 3 [/SUP], Garima Mittal[SUP] 4 [/SUP], Anita Sharma[SUP] 5 [/SUP], Naveen Bansal[SUP] 6 [/SUP]
Affiliations
Abstract
The only effective way to provide individuals with herd immunity against the novel coronavirus [SARS-CoV-2] is to administer an effective vaccine that will help check the current pandemic status. In India, the central drugs standard control organization (CDSCO) has granted the emergency-use authorization [EUA] to three vaccines namely, Covishield (live vaccine, Oxford AstraZeneca, United Kingdom being manufactured by the Serum Institute of India), Covaxin (inactivated vaccine, Bharat Biotech, India) and Sputnik V (live vaccine, Gamaleya, Russia). However, there is a rising need for the efficacy of the vaccines to be proven against the "SARS-CoV-2 viral variants." Also, human plasma is polyclonal in nature with an inherent propensity to identify multiple epitopes of either an antigen or pathogen. With this context in mind, the researchers hypothesize that using COVID-19 convalescent plasma [CCP] harvested from the locally recovered individuals [i.e. potential CCP donors] may be particularly beneficial in combating not only the founder SARS-CoV-2 virus but also the geographically confined SARS-CoV-2 variants among the regionally affected COVID-19 patients.
Keywords: Blood Donors; Blood Safety; Donor Registry; Pandemic; Vaccine Impact; Viral Variants, COVID-19 Convalescent Plasma.
. 2021 May 7;S1246-7820(21)00073-2.
doi: 10.1016/j.tracli.2021.05.003. Online ahead of print.
Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants
Manish Raturi[SUP] 1 [/SUP], Anuradha Kusum[SUP] 2 [/SUP], Mansi Kala[SUP] 3 [/SUP], Garima Mittal[SUP] 4 [/SUP], Anita Sharma[SUP] 5 [/SUP], Naveen Bansal[SUP] 6 [/SUP]
Affiliations
- PMID: 33971318
- DOI: 10.1016/j.tracli.2021.05.003
Abstract
The only effective way to provide individuals with herd immunity against the novel coronavirus [SARS-CoV-2] is to administer an effective vaccine that will help check the current pandemic status. In India, the central drugs standard control organization (CDSCO) has granted the emergency-use authorization [EUA] to three vaccines namely, Covishield (live vaccine, Oxford AstraZeneca, United Kingdom being manufactured by the Serum Institute of India), Covaxin (inactivated vaccine, Bharat Biotech, India) and Sputnik V (live vaccine, Gamaleya, Russia). However, there is a rising need for the efficacy of the vaccines to be proven against the "SARS-CoV-2 viral variants." Also, human plasma is polyclonal in nature with an inherent propensity to identify multiple epitopes of either an antigen or pathogen. With this context in mind, the researchers hypothesize that using COVID-19 convalescent plasma [CCP] harvested from the locally recovered individuals [i.e. potential CCP donors] may be particularly beneficial in combating not only the founder SARS-CoV-2 virus but also the geographically confined SARS-CoV-2 variants among the regionally affected COVID-19 patients.
Keywords: Blood Donors; Blood Safety; Donor Registry; Pandemic; Vaccine Impact; Viral Variants, COVID-19 Convalescent Plasma.